Table 3.
Overall incidence of outcomes: unadjusted analysis
| RAL | Historical | Concurrent | |||||||
|---|---|---|---|---|---|---|---|---|---|
| No. of events | PYFU | Incidence per 100 PYFU (95% CI) | No. of events | PYFU | Incidence per 100 PYFU (95% CI) | No. of events | PYFU | Incidence per 100 PYFU (95% CI) | |
| Malignancies | 50 | 4505.0 | 1.11 (0.84, 1.46) | 45 | 3748.5 | 1.20 (0.90, 1.61) | 127 | 15 247 | 0.83 (0.70, 0.99) |
| Clinically important hepatic events | 3 | 4583.0 | 0.07 (0.02, 0.20) | 41 | 3750.8 | 1.09 (0.80, 1.48) | 38 | 15 379 | 0.25 (0.18, 0.34) |
| Lipodystrophy | 14 | 4559.9 | 0.31 (0.18, 0.52) | 77 | 3712.0 | 2.07 (1.66, 2.59) | 98 | 15 238 | 0.64 (0.53, 0.78) |
| Mortality | 47 | 4656.2 | 1.01 (0.76, 1.34) | 34 | 3780.2 | 0.90 (0.64, 1.26) | 116 | 15 500 | 0.75 (0.62, 0.90) |
CI, confidence interval; PYFU, person‐years of follow‐up; RAL, raltegravir.